| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C20H22ClNO |
| Molar mass | 327.85 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
AL-1095,[1] is a centrally actingstimulant drug with comparable effects toamphetamine,[2] developed by Bristol in the 1970s.[3]

The first-step is a mixed-aldol condensation between 3-quinuclidinone [3731-38-2] (1) andbenzaldehyde (2) gives 2-benzylidene-3-oxoquinuclidine [24123-89-5] (3). The conjugate addition of the Grignard reagent formed from 4-bromochlorobenzene [106-39-8] (4) to the enone gives the benzhydryl (5).MPV reduction of the carbonyl gives the syn stereoisomers, whereas borohydride gave trans. Both diastereoisomers are active but in only one of the enantiomers.
Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |